Hung Trinh: Precigen Scores FDA Nod for First Treatment of an HPV-Related Disorder
Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:
“Precigen scores FDA nod for first-ever treatment for HPV-related disorder.
For the first time, the FDA has approved a treatment for recurrent respiratory papillomatosis (RRP), a rare, chronic disease that causes benign tumors, most commonly in the voice box, and can force some patients to endure hundreds of surgeries to remove the growths.
Making the grade is Precigen’s Papzimeos (zopapogene imadenovec-drba), a first-of-its-kind non-replicating adenoviral vector-based immunotherapy, which can eliminate the need for repeated surgical interventions.
Papzimeos, which is administered by a subcutaneous injection, triggers an immune response against cells infected with human papillomavirus (HPV) types 6 and 11, which cause RRP. Four shots are administered over the course of three months, providing patients with what is expected to be long-term protection against the emergence of the tumors, also called papillomas.”
More posts featuring Hung Trinh.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023